Survival and Prognostic Factors in Adult Low-Grade Gliomas

Yıl 2016, Cilt: 5 Sayı: 3, 173 - 180, 01.09.2016

Suheyla Aytaç Arslan Muzaffer Bedri Altundağ Ela Soykut Gonca Altınışık İnan Yıldız Güney

https://doi.org/10.5505/abantmedj.2016.19327

Öz

INTRODUCTION: The purpose of this study was to evaluate survival in patients with nonpilocytic low-grade gliomas LGGs .METHODS: Records of 70 adult patients with LGGs diagnosed between 2003 and 2007 at Dr Abdurrahman Yurtarslan Oncology, Education and Research Hospital AOH , Ankara, Turkey, were retrospectively reviewed. The Kaplan-Meier method estimated overall survival OS .RESULTS: Median age at diagnosis was 37.5 years range; 20- 73 with a slightly higher male predominance male / female: 1.26 . Median follow-up was 39 range, 4-79 months. Operative pathology revealed pure astrocytoma in 54% oligodendroglioma in 21%, and oligoastrocytoma in 10% of patients. Subtotal resection STR was achieved in 44 patients 63% , gross total resection GTR in 19 27% , and biopsy only in 7 10% . Presenting symptoms in order of frequency were headache, seizure and motor disturbances. Median time interval between surgery and radiotherapy was 7 weeks ranging from 3 to 78. Median OS was 71 months range, 4-80 months .DISCUSSION AND CONCLUSION: Survival was not significantly influenced by age, gender, extent of resection, tumor size, histology and time interval between surgery and radiotherapy. Statistically significant good prognostic factors for OS was Karnofsky Performance Status KPS > 70 p < 0.001 .

Anahtar Kelimeler

Low-grade gliomas, Radiotherapy, Prognostic factors, Overall survival

Yetişkin Düşük Dereceli Gliomlarda Sağkalım ve Prognostik Faktörler

Öz

GİRİŞ ve AMAÇ: Pilositik olmayan düşük dereceli gliomlarda sağkalım değerlendirmek.YÖNTEM ve GEREÇLER: 2003-2007 yılları arasında Ankara Onkoloji Eğitim ve Araştırma Hastanesinde AOH Düşük Dereceli Glial Tümör tanısıyla tedavi edilen 70 erişkin hasta geriye dönük olarak incelendi. Genel Sağkalım GSK tahminleri Kaplan Meier ile yapıldı.BULGULAR: Ortanca yaş 37.5 aralık; 20-73 ve erkek çoğunlukdaydı erkek/kadın: 1.26 . Ortanca takip süresi 39 aydı aralık; 4-79 . Cerrahi sonucu hastaların %54'ünün saf astrositom, %21'inin oligodendrogliom, %10'unun ise oligoastrositom olduğu belirlendi. Hastaların 44'üne %63 subtotal rezeksiyon STR , 19'una %27 gross total rezeksiyon GTR ve 7'sine %10 biopsi uygulandı. Başvuru şikayeti sıklık sırasıyla başağrısı, nöbet ve motor bozukluktu. Cerrahi ile radyoterapi arasındaki ortanca süre 7 hafta olup, 3 hafta ile 78 hafta arasında değişmekteydi. Ortanca GSK 71 ay aralık, 4-80 ay olarak bulundu.TARTIŞMA ve SONUÇ: Sağkalım; yaş, cinsiyet, tümör boyutu, histolojik tip ve cerrahi sonrası radyoterapi başlama zamanından istatistiki olarak anlamlı derecede etkilenmemiştir. Karnofsky Performans skorunun KPS 70'in üstünde olması istatistiksel olarak anlamlı iyi prognostik faktördür p < 0.001 .

Anahtar Kelimeler

Düşük dereceli gliomlar, Radyoterapi, Prognostik Faktörler, Genel Sağkalım

Kaynakça

• Sherman JH, Weintraub D, Lopes MBS, Schiff D. Low-Grade Gliomas. In: Norden AD et al editors. Primary central nervous system tumors, Pathogenesis and Therapy. New York: Humane Press, 2011: Part 2, p.173-194.
• Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009; 10: 231-42.
• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 200 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97–109.
• Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, et al. European Federation of Neurological Societies. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010; 17: 1124-33.
• Pouratian N, Mut M, Jagannathan J, Lopes MB, Shaffrey ME, Schiff D. Low-grade gliomas in older patients: a retrospective analysis of prognostic factors. J Neurooncol. 2008; 90: 341-50.
• Sanders WP, Christoforidis GA. Imaging of low-grade primary brain tumors. In: Rock JP et al editors. The practical management of low Philadelphia: Lippincott Williams & Wilkins, 1999: p.5-32. brain tumors.
• Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O'Neill BP et al. Intracranial low- grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol. 2009; 11: 437-45.
• Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma. Int J Radiat Oncol Biol Phys. 1996; 36: 549-56.
• van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K et al. Long-term efŞcacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults. Lancet. 2005; 366: 985-90. Erratum in: Lancet. 2006; 367: 1818.
• Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, et al Prospective randomized trial of low- versus high-dose radiation supratentorial low-grade glioma. J Clin Oncol. 2002; 20: 2267-76. in adults with
• Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol. 1997; 15: 3129-40.
• Shaw EG, Scheithauer BW, O’Fallon JR. Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol. 1997; 31: 273–8.
• Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg. 1993: 78: 909–14.
• Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003; 21: 646–51.
• SofŞetti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998; 43: 1066–73. recurrent
• van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology. 1998; 51: 1140–5.
• van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of Şrst-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003; 21: 2525–8.
• Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 2006; 106: 1358–63.
• Bauman G, Pahapill P, Macdonald D, Fisher B, Leighton C, Cairncross G. Low grade glioma: A measuring radiographic response to radiotherapy. Can J Neurol Sci. 1999; 26: 18– 22.
• Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D. Adult supratentorial low-grade glioma: long-term experience at a single institution. Int J Radiat Oncol Biol Phys. 2009; 75: 1401-7.
• Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello-lacono D, Talos F, Jolesz FA, Black PM. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005; 103: 1227–33.
• Bello L, Gallucci M, Fava M, Carrabba G, Giussani C, Acerbi F, Baratta P, Songa V, Conte V, Branca V, Stocchetti N, Papagno C, Gaini SM. Intraoperative subcortical language tract mapping guides surgical removal of gliomas involving speech areas. Neurosurgery. 2007; 60: 67–80
• Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS. Role of extent of resection in the long-term outcome of low- grade hemispheric gliomas. J Clin Oncol. 2008; 26: 1338–45.
• Duffau H. Surgery of low-grade gliomas: towards a functional neurooncology. Curr Opin Oncol. 2009; 21: 543–9.
• Janny P, Cure H, Mohr M, Heldt N, Kwiatkowski F, Lemaire JJ, et al. Low grade supratentorial astrocytomas: management and prognostic factors. Cancer. 1994; 73: 1937–45.
• Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997; 15: 1294–301.
• Van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998; 64: 581–7. factors
• Grabenbauer GG, Roedel CM, Paulus W, Ganslandt O, Schuchardt U, Buchfelder M, et al. Supratentorial low-grade glioma: results and postoperative radiotherapy. Strahlenther Onkol. 2000; 176: 259–64. following
• Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). Eur J Cancer. 1998; 34.